share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K：外國發行人報告
美股sec公告 ·  05/14 09:04
Moomoo AI 已提取核心訊息
On May 14, 2024, NeuroSense Therapeutics announced a partnership with PhaseV to enhance the upcoming Phase 3 trial of PrimeC for ALS treatment using advanced causal machine learning. PhaseV's analysis of NeuroSense's Phase 2b PARADIGM study predicts a high probability of success in multiple ALS subgroups for the Phase 3 trial. The insights gained will inform study design and patient enrollment, aiming to maximize clinical results and market differentiation for PrimeC. NeuroSense recently reported positive results from the PARADIGM trial, showing a significant slowing in disease progression, and plans to submit its End of Phase 2 package to the FDA and EMA soon. PhaseV's technology aids in optimizing clinical trial design by identifying likely successful subgroups and endpoints. NeuroSense focuses on developing treatments for neurodegenerative diseases, with a primary focus on ALS.
On May 14, 2024, NeuroSense Therapeutics announced a partnership with PhaseV to enhance the upcoming Phase 3 trial of PrimeC for ALS treatment using advanced causal machine learning. PhaseV's analysis of NeuroSense's Phase 2b PARADIGM study predicts a high probability of success in multiple ALS subgroups for the Phase 3 trial. The insights gained will inform study design and patient enrollment, aiming to maximize clinical results and market differentiation for PrimeC. NeuroSense recently reported positive results from the PARADIGM trial, showing a significant slowing in disease progression, and plans to submit its End of Phase 2 package to the FDA and EMA soon. PhaseV's technology aids in optimizing clinical trial design by identifying likely successful subgroups and endpoints. NeuroSense focuses on developing treatments for neurodegenerative diseases, with a primary focus on ALS.
2024年5月14日，NeuroSense Therapeutics宣佈與PhasEV建立合作伙伴關係，以加強即將進行的使用高級因果機器學習進行肌萎縮性側索硬化症治療的PrimeC的3期試驗。PhaseV對NeuroSense的2b期PARADIGM研究的分析預測，在3期試驗的多個肌萎縮性側索硬化症亞組中，成功的可能性很高。獲得的見解將爲研究設計和患者入組提供信息，旨在最大限度地提高PrimeC的臨床結果和市場差異化。NeuroSense最近報告了PARADIGM試驗的積極結果，顯示疾病進展顯著放緩，並計劃儘快向美國食品藥品管理局和歐洲藥品管理局提交其第二階段結束套餐。PhaseV的技術通過識別可能成功的子組和終點來幫助優化臨床試驗設計。NeuroSense專注於開發神經退行性疾病的治療方法，主要關注肌萎縮性側索硬化症。
2024年5月14日，NeuroSense Therapeutics宣佈與PhasEV建立合作伙伴關係，以加強即將進行的使用高級因果機器學習進行肌萎縮性側索硬化症治療的PrimeC的3期試驗。PhaseV對NeuroSense的2b期PARADIGM研究的分析預測，在3期試驗的多個肌萎縮性側索硬化症亞組中，成功的可能性很高。獲得的見解將爲研究設計和患者入組提供信息，旨在最大限度地提高PrimeC的臨床結果和市場差異化。NeuroSense最近報告了PARADIGM試驗的積極結果，顯示疾病進展顯著放緩，並計劃儘快向美國食品藥品管理局和歐洲藥品管理局提交其第二階段結束套餐。PhaseV的技術通過識別可能成功的子組和終點來幫助優化臨床試驗設計。NeuroSense專注於開發神經退行性疾病的治療方法，主要關注肌萎縮性側索硬化症。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息